Inventor · disambiguated record
Patrick Mayes
Also filed as: MAYES PATRICK · MAYES PATRICK A
12 granted patents·24 pending applications·138 citations·filing 2012–2025
90Inventor score
Top patents by PatentIndex Score
36 records- 0196US9771424B2ICOS binding proteinsGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Granted Sep 26, 2017·30 cites·20 claims
- 0296US9738718B2ICOS binding proteinsGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Granted Aug 22, 2017·33 cites·20 claims
- 0396US9273141B2B cell maturation antigen (BCMA) binding proteinsGLAXO GROUP LTD·Filed 2013·Granted Mar 1, 2016·68 cites·15 claims
- 0487US11993654B2PD-1 binding domainsMERUS NV·Filed 2022·Granted May 28, 2024·1 cites·20 claims
- 0584US11130811B2ICOS binding proteinsGLAXOSMITHKLINE IP DEV LTD·Filed 2019·Granted Sep 28, 2021·1 cites·18 claims
- 0681US12466893B2Antigen binding proteinsGLAXO GROUP LTD·Filed 2022·Granted Nov 11, 2025·0 cites·31 claims
- 0777US11353458B2Prognostic methodGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Granted Jun 7, 2022·4 cites·8 claims
- 0877US2022064299A1Icos binding proteinsGLAXOSMITHKLINE IP DEV LTD·Filed 2021·Application pending·0 cites
- 0976US12227585B2Anti-BCMA antibody drug conjugate combination treatment for cancerGLAXOSMITHKLINE IP DEV LTD·Filed 2023·Granted Feb 18, 2025·0 cites·20 claims
- 1076US10351627B2ICOS binding proteinsGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Granted Jul 16, 2019·1 cites·22 claims
- 1176US2024425594A1Novel pd-1 binding domainsMERUS NV·Filed 2024·Application pending·0 cites
- 1276US2024425595A1Novel pd-1 binding domainsMERUS NV·Filed 2024·Application pending·0 cites
- 1375US2025122297A1Anti-BCMA Antibody Drug Conjugate Combination Treatment for CancerGLAXOSMITHKLINE IP DEV LTD·Filed 2024·Application pending·0 cites
- 1472US12234293B2Treatment for primary amyloidosis with anti-BCMA binding proteinGLAXOSMITHKLINE IP DEV LTD·Filed 2022·Granted Feb 25, 2025·0 cites·19 claims
- 1571US11419945B2Antigen binding proteinsGLAXO GROUP LTD·Filed 2020·Granted Aug 23, 2022·0 cites·15 claims
- 1671US2020140551A1Icos binding proteinsGLAXOSMITHKLINE IP DEV LTD·Filed 2019·Application pending·0 cites
- 1765US2018334503A1Icos binding proteinsGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 1865US2024218070A1FAP BINDING DOMAINS AND BISPECIFIC BINDING MOIETIES THAT BIND FAP AND TGF-ßRIIMERUS NV·Filed 2023·Application pending·0 cites
- 1963US2018147293A1Antigen binding proteinsGLAXO GROUP LTD·Filed 2017·Application pending·0 cites
- 2062US2023250190A1Binding domains against cancer-associated muc1MERUS NV·Filed 2022·Application pending·0 cites
- 2162US2017313777A1Icos binding proteinsGLAXOSMITHKLINE IP DEV LTD·Filed 2017·Application pending·0 cites
- 2261US2025163172A1Combination Treatment for CancerGLAXOSMITHKLINE IP DEV LTD·Filed 2025·Application pending·0 cites
- 2360US2024101718A1Anti-pd-1/lag-3 bispecific antibodies and uses thereofINCYTE CORP·Filed 2023·Application pending·0 cites
- 2459US11401334B2Combination treatment for cancer with anti-BCMA binding protein and proteosome inhibitorGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Granted Aug 2, 2022·0 cites·5 claims
- 2559US2016193358A1Antigen binding proteinsGLAXO GROUP LTD·Filed 2015·Application pending·0 cites
- 2659US2023159645A1Multispecific binding moieties comprising pd-1 and tgf-brii binding domainsMERUS NV·Filed 2022·Application pending·0 cites
- 2758US2022411512A1Combination treatment for cancerGLAXOSMITHKLINE IP DEV LTD·Filed 2022·Application pending·0 cites
- 2858US2023272055A1Anti-mutant calreticulin (calr) antibodies and uses thereofINCYTE CORP·Filed 2022·Application pending·0 cites
- 2956US2022363761A1Multispecific binding moieties comprising novel pd-1 binding domainsMERUS NV·Filed 2022·Application pending·0 cites
- 3051US2020255526A1Combination treatment for cancerGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 3149US2020254093A1Combination treatment for cancerGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 3238US2014105915A1Bcma (cd269/tnfrsf17) - binding proteinsALGATE PAUL·Filed 2012·Application pending·0 cites
- 3336US2020190194A1Combination therapyGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 3433US2020181275A1Combination therapy with icos agonist and ox40 agonist to treat cancerGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 3533US2020190195A1Combination therapy with icos agonist and ox40 agonist to treat cancerGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 3625US2019256608A1Combination treatments and uses and methods thereofGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Patrick Mayes files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →